News and insights

FDA lifts clinical hold on investigational lenacapavir for the treatment and prevention of HIV.

Update on CheckMate -901 trial evaluating Opdivo + Yervoy as first-line treatment for metastatic urothelial carcinoma

NMPA (China) approves Tuoyi to treat unresectable locally advanced/ recurrent or distant metastatic esophageal squamous cell carcinoma.

Taiho acquires Cullinan Pearl and rights to CLN 081/TAS 6417.

NMPA (China) approves Verkazia to treat vernal keratoconjunctivitis (VKC) in children and adolescents.- Santen

FDA approves Radicava ORS, oral suspension, to treat amyotrophic lateral sclerosis.- Mitsubishi Tanabe

NICE (UK) recommends selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis.- AstraZeneca + Merck Inc.

National Institute for Health and Care Excellence (NICE) recommends relugolix combination therapy to treat uterine fibroids.- Gedeon Richter.

FDA approval for Onyx Frontier, the latest generation drug-eluting coronary stent system.- Medtronic

New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in moderate to severe plaque psoriasis. - BMS

FDA approves Mounjaro injection, the first and only once weekly GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. - Eli Lilly.

NVX-CoV2373 vaccine is filed for Emergency Use Authorization to prevent COVID 19 in Taiwan. Novavax

U.S commercial launch of the UroLift 2 system and UroLift ATC advanced tissue control system to manage benign prostatic hyperplasia.- Teleflex Inc.

Symplicity Spyral RND system demonstrates significant blood pressure reduction through three years.

Rinvoq achieved clinical remission and endoscopic response at one year in phase III maintenance study in patients with Crohn's disease

Complete Response Letter for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.

Phase III MOMENTUM study of CYT 387 in myelofibrosis presented at 2022 Annual Meeting of the European Hematology Association.

MHLW (Japan) in its COVID-care guide cites reduced efficiency of Xevudy against BA 2 Omicron sub-variant

Pfizer to acquire Biohaven and with it Nurtec ODT a treatment for migraine

Phase III MELODY and Phase IIb trials of MEDI 8897 shows efficacy in RSV.

FDA approves Olumiant for COVID-19.

Interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer.

Incyte and Maruho announce strategic alliance agreement for ruxolitinib cream in Japan.

Phase III FURI study of ibrexafungerp shows positive outcomes in vulvovaginal candidiasis.

European Commission marketing authorisation for PreHevbri, a 3-antigen adult hepatitis B vaccine.

European Commission approval of Kymriah as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma.

Quviviq is granted EU approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder.

Impact of inappropriate care and disability accumulation on quality of life in FOP

The unpredictable nature of flare-ups in fibrodysplasia ossificans progressiva (FOP)

From soft-tissue to bone: Clinical presentation of fibrodysplasia ossificans progressiva (FOP)

Clinical value beyond price alone: anti-TNF biosimilars enable early treatment

Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases

Clinical value beyond price alone: biosimilars improve patient access to treatment

Long-term topical management of psoriasis: the road ahead

Over the horizon: early stage trials for NASH

Phase II trials and stem cell therapies

The next global epidemic

The latest treatments in NASH

The future of organ transplantation

Complications of stem cell transplants

Challenges in transplant organ rejection

Treating rejection in organ transplants

Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups

Antibody-drug conjugates (ADCs)

Cancer immunotherapies

Left ventricular assist devices – A viable therapeutic option for heart failure?

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

How close are we to a disease-modifying treatment for Alzheimer’s?

Biologic efficacy for complications associated with moderate-to-severe psoriasis

Moderate-to-severe psoriasis: treatment for young women

Chronic myelogenous leukaemia: a remarkable success story

Unravelling the microbiome - health through happy communities

Part two | New hopes for treatment in the global obesity epidemic

Inactivity in the elderly increases their cardiovascular risk by 14%

Type 2 diabetes risk may be increased by statin use in susceptible individuals

New hyperammonaemia resource developed for Medthority.com users

Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?

Launch of updated Hypogonadism Knowledge Centre

Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet

Key findings from the SWIPE study

Focus on Primary Care - helping GPs diagnose, manage and treat urticaria

Free haemato-oncology report added to AIKN-IFI congresses section

Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre

Part Three | Next generation obesity therapies

Medical cannabis - a novel approach to pain control

Immobility and sleep disruption in the ICU - Latest recommendations

ESOT 2015 speaker slides added to AIKN-IFI

Prof Vincent interview - Defining the eCASH Concept in PAD Management

New: Symposium videos & presentations for immunologists, dermatologists and allergists

Appetite and the brain - white matter integrity to blame?

Magnetic nanoparticles could help rejuvenate damaged hearts

SGLT2 Inhibitors: good news for diabetes

Long-term disease control in Psoriasis: announcing a new project

Targeted therapies in triple negative breast cancer

Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease

Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future

Opioids - Over the horizon

From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)

New approaches to anticoagulant therapy

Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)

Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre

Horizons: a series of opinion & insight articles on disruptive healthcare in practice

Launch of Chronic Spontaneous Urticaria CME activity

New findings may pave the way for novel HIV drugs

ATS 2015 symposium materials added to COPD Knowledge Centre

Replacement therapies for opioid drugs in pain treatment

Launch of new Cystic Fibrosis Knowledge Centre

Acute myeloid leukaemia: Hope for new treatments

Adoptive T cell therapy, advanced melanoma and survival

An independent review of current treatments for migraine

Launch of LAL-Deficiency Knowledge Centre

Migraine treatments: On the horizon

Psoriasis Knowledge Centre relaunches on Medthority.com

New rare disease platform launched for Hunter Syndrome

Vitamin D in pregnancy - is it any good?

New type 2 diabetes CME activity now available on Medthority.com

Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com

IL-17A treatment section added to Psoriasis Knowledge Centre

Close social relationships may slow cognitive decline

Microbiomes: is there nothing that they can't do?

Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries

Senolytics: Can we treat age-related diseases with a single drug

Opioids: the future and challenging the epidemic

New inflammatory bowel disease (IBD) Knowledge Centre

Opioids: The war on drugs

Targeted therapies in HER2 positive breast cancer

Atopic Dermatitis Knowledge Centre launched on Medthority.com

New publication digest and infographic for Cardiologists.

Genetic variation and drug efficacy - could this pave the way for personalised medicines?

Shaken not stirred your bacteriophage cocktail

WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre

Bedwetting resource receives a mobile-friendly transformation

Breast Cancer- Targeted therapies

Launch of Oral Anticoagulation Reversal Knowledge Centre

NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com

COPD experts tackle key topics in our latest Q&A

World Congress of Dermatology 2019 - A new ERA for global Dermatology

UPDATE: Urticaria e-learning new modules & symposia highlights

Nonalcoholic steatohepatitis: the next global epidemic?

Migraine: The forgotten epidemic?

Your guide to IBD novel treatments and assessment tools

Launch of new Chronic Lymphocytic Leukaemia CME

Schizophrenia: challenges in a crowded market

Targeted therapies in HER2 negative breast cancer

The way ahead for cystic fibrosis

Japan's aging population and Alzheimer's